The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A New Therapeutic Monoclonal Antibody Targeting CD302 In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This project will develop a new antibody treatment for Acute Myeloid Leukaemia. Antibody treatments help the body to attack the leukaemia using its immune system. The prognosis of this leukaemia is poor. Our current treatments use high dose chemotherapy and sometimes a stem cell transplant. Many patients cannot have the current therapy due to their age or other medical problems. A new antibody therapy may be used on its own or with other therapies to help more patients achieve remission.
The Mechanism And Application Of A Superagonistic Antibody For Human IL-21.
Funder
National Health and Medical Research Council
Funding Amount
$95,313.00
Summary
Monoclonal antibodies are widely used in diagnosis and therapy due to their outstanding specificity and safety. The monoclonal antibodies recognizing cytokines with enhancing functions are an emerging class of novel reagents in immunotherapy. This project is to investigate how a newly indentified monoclonal antibody enhances the activity of a cytokine and use this immunostimulatory function to design new strategies for better vaccination and treatment for cancer and infection.
CD300f As A Novel Therapeutic Antibody Target In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$89,926.00
Summary
This study aims to develop a new antibody therapy for Acute Myeloid Leukaemia (AML), the most common type of leukaemia in adults. We will study the function of CD300f, a new receptor found on the surface of both healthy blood cells and the cancer cells in AML. We will investigate whether blocking this receptor with a newly developed antibody can be used to kill cancer cells. It is hoped that this study will allow development of this antibody for use in a future clinical trial.
Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and l ....Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and lead to a personalized treatment of rectal cancer.Read moreRead less
Big Data To Inform The Impact Of Antibiotics And Proton Pump Inhibitors On Immunotherapies Used To Treat Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$115,883.00
Summary
Antibiotics and proton pump inhibitors (PPIs) affect gut bacteria health. Gut bacteria are involved in the function of the immune system and potentially the effectiveness of immunotherapies. However, the impact of antibiotics and PPIs on the efficacy of immunotherapies is unknown. Newly available big data will be used to determine the impacts of antibiotics and PPIs on immunotherapy efficacy, informing on the best cancer treatments to use in patients who require antibiotics or PPIs.
Antibody Targeted Virus Particles For A Gene Therapy Approach To Inhibiting Atheroschlerosis Development
Funder
National Health and Medical Research Council
Funding Amount
$95,313.00
Summary
I am a Biotechnologist and my research looks into ways of preventing Atherosclerosis. Atherosclerosis is the build up of plaques in artery walls, and is the major precursor condition to stroke and myocardial infarction (heart attack). My project focuses on a preventative gene therapy which will be delivered specifically to early stage plaques. The gene will inhibit one of the earliest developmental stages of atherosclerosis: recruitment of immune cells to these sites, and so prevent their growth ....I am a Biotechnologist and my research looks into ways of preventing Atherosclerosis. Atherosclerosis is the build up of plaques in artery walls, and is the major precursor condition to stroke and myocardial infarction (heart attack). My project focuses on a preventative gene therapy which will be delivered specifically to early stage plaques. The gene will inhibit one of the earliest developmental stages of atherosclerosis: recruitment of immune cells to these sites, and so prevent their growth.Read moreRead less
CLINICAL CHARACTERIZATION OF GENETICALLY DEFINED GERMLINE SUB-GROUPS OF MELANOMA AND BREAST CANCER PATIENTS.
Funder
National Health and Medical Research Council
Funding Amount
$140,949.00
Summary
In this project I will assess how cancer patients’ genetic makeup influences the nature and outcome of their cancer, especially in terms of how successful treatment is likely to be. We will show how key genetic variants influence cancer behaviour and by combining these genes we will have a better understanding of how to develop more successful treatments.
Understanding And Manipulating The Epigenetic Networks That Define Osteosarcoma
Funder
National Health and Medical Research Council
Funding Amount
$80,467.00
Summary
Osteosarcoma is the most common type of bone cancer and the fifth most common form of cancer in children. Although osteosarcoma begins in bones, the cancer often spreads to other parts of the body. Patients have a very poor chance of survival if their cancer has spread. We will use mouse and human models of osteosarcoma to improve our understanding of how the cancer is different from the normal bone forming cells. This information will help us to find new treatments to improve patient outcomes.
Use Of Circulating Tumour DNA To Characterise The Mutational Landscape Of Marginal Zone Lymphoma, Monitor Treatment Response And Detect Emergence Of Resistance
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Marginal zone lymphoma (MZL) is a subtype of B-cell non-Hodgkin lymphoma for which the molecular drivers of disease are poorly understood. We hypothesise that circulating tumour DNA may be ideal for characterising the genetic mutations that underpin MZL, monitoring treatment response and detecting emergence of resistance. This non-invasive method of disease monitoring has the potential to transform management of cancers such as MZL, identify new treatment options and improve survival outcomes.
Understanding The Molecular Basis Of Inherent And Acquired Resistance To Targeted Therapies In Metastatic Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$107,750.00
Summary
Targeted therapies aim to block cancer growth by interfering with specific molecules needed for its development and progression. Targeted therapies have led to improved responses and survival in patients with metastatic colorectal cancer. However, not all patients benefit from these treatments, and most patients who do respond eventually develop resistance. The aim of this research is to understand the mechanisms of resistance to these treatments, in order to improve their use in patients.